[go: up one dir, main page]

WO2006113236A3 - Novel chemical inhibitors of neutrophil activation through the sac-dependent pathway - Google Patents

Novel chemical inhibitors of neutrophil activation through the sac-dependent pathway Download PDF

Info

Publication number
WO2006113236A3
WO2006113236A3 PCT/US2006/013537 US2006013537W WO2006113236A3 WO 2006113236 A3 WO2006113236 A3 WO 2006113236A3 US 2006013537 W US2006013537 W US 2006013537W WO 2006113236 A3 WO2006113236 A3 WO 2006113236A3
Authority
WO
WIPO (PCT)
Prior art keywords
sac
novel chemical
dependent pathway
neutrophil activation
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/013537
Other languages
French (fr)
Other versions
WO2006113236A2 (en
Inventor
Carl F Nathan
Jochen Buck
Lonny R Levin
Hyunsil Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of WO2006113236A2 publication Critical patent/WO2006113236A2/en
Publication of WO2006113236A3 publication Critical patent/WO2006113236A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method of treating an inflammatory disorder in a subject. The method involves administering to a subject an effective amount of a compound that modulates soluble adenylyl cyclase, thereby treating the inflammatory disorder in the subject. The present invention also relates to a method of inhibiting respiratory burst in adherent neutrophils without inhibiting neutrophil degranulation in or bacterial killing by neutrophils. The method involves contacting adherent neutrophils with an effective amount of a compound that modulates soluble adenylyl cyclase.
PCT/US2006/013537 2005-04-14 2006-04-12 Novel chemical inhibitors of neutrophil activation through the sac-dependent pathway Ceased WO2006113236A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67140805P 2005-04-14 2005-04-14
US60/671,408 2005-04-14

Publications (2)

Publication Number Publication Date
WO2006113236A2 WO2006113236A2 (en) 2006-10-26
WO2006113236A3 true WO2006113236A3 (en) 2007-05-31

Family

ID=37115668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013537 Ceased WO2006113236A2 (en) 2005-04-14 2006-04-12 Novel chemical inhibitors of neutrophil activation through the sac-dependent pathway

Country Status (1)

Country Link
WO (1) WO2006113236A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP2083819B1 (en) * 2006-11-21 2017-02-22 Omeros Corporation Pde10 inhibitors and related compositions and methods
WO2010096830A2 (en) 2009-02-23 2010-08-26 Cornell University Method to treat psoriasis and other hyperproliferative skin disorders
CN111676265B (en) * 2020-05-29 2021-06-15 威海市立医院 Method for detecting phagocytic capacity of neutrophil

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
US6403358B1 (en) * 1999-10-05 2002-06-11 Millennium Pharmaceuticals, Inc. 21529, a novel adenylate cyclase
US6468756B1 (en) * 1999-02-22 2002-10-22 Synaptic Pharmaceutical Corporation Methods of identifying compounds that bind to SNORF25 receptors
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
US6468756B1 (en) * 1999-02-22 2002-10-22 Synaptic Pharmaceutical Corporation Methods of identifying compounds that bind to SNORF25 receptors
US6403358B1 (en) * 1999-10-05 2002-06-11 Millennium Pharmaceuticals, Inc. 21529, a novel adenylate cyclase

Also Published As

Publication number Publication date
WO2006113236A2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
WO2008019395A3 (en) Compounds for improving learning and memory
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2006113942A3 (en) Method of inhibiting cathepsin activity
MX2009004984A (en) Methods for preserving renal function using xanthine oxidoreductase inhibitors.
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
WO2008070041A3 (en) Inhibitors of akt activity
WO2008126374A1 (en) Agent for improving alkali resistance of plant and method for improving alkali resistance of plant
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2006135627A3 (en) Inhibitors of akt activity
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
WO2008039421A3 (en) Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
MX2009004061A (en) Organic compounds.
MX2009005649A (en) Treatment for multiple myeloma.
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
MX348514B (en) Potentiated biocidal compositions and methods of use.
WO2007117680A3 (en) Methods and compositions for treating bacterial infection
WO2006125539A3 (en) Combination therapy comprising diaryl ureas for treating diseases
WO2011081945A3 (en) Activation and activators of sirt6
WO2007144057A3 (en) Antimicrobial carbon
WO2008063676A3 (en) Treatment of injury to the brain by inhibition of acid sensing ion channels
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
WO2007085760A3 (en) Anti-infective solution comprising a compound of pyrido(3,2,1-ij)-benzoxadiazine type

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749801

Country of ref document: EP

Kind code of ref document: A2